FDA: Drugs Under Scrutiny
In my opinion the FDA is hit or miss. Sometimes they’re right on the money. And other times, like with the cattle drugs, they’re in La La Land. Well, maybe this redeems them a little. According to Miranda Hitti of WebMD Medical News, the FDA has pulled 15 migraine drugs off the market:
The FDA today announced that it has ordered 15 unapproved migraine drugs containing ergotamine off the market.And they’re not stopping there. Steven Reinberg of HealthDay News reports that the FDA will review children’s cold remedies because of their potential health risks:
Those drugs, sold only by prescription, lack a required "black box" safety warning and haven't been reviewed by the FDA for safety and efficacy.
The unapproved ergotamine drugs are unrelated to migraine drugs called triptans such as Imitrex, Zomig, and Maxalt.
Dr. Charles Ganley, the FDA's director of the Office of Nonprescription Products, said the agency has been "looking into the issue of safety of children's cough medicine since the middle of last year." He noted that when these medicines were originally approved, in some cases several decades ago, there was no mandate that the effectiveness, safety or dose be determined for children; rather, the guidelines were extrapolated from studies done with adults.Now this is all well and good, but I’m sure some day soon they’ll approve the sale of diet pills linked to chronic stupidity—wait, that might have happened already.
"We have not established a dose that is safe for children 2 and under," Ganley said during a teleconference. "We hope to have our review done in several months and then make recommendations."
Trackbacks (0) Links to blogs that reference this article Trackback URL
Dr. Fuhrman's Executive Offices
4 Walter E. Foran Blvd.Flemington, NJ 08822